Wiskott-Aldrich Syndrome (WAS)

1. Overview
2. The Classic Triad
3. Disease Spectrum
4. Complications
5. Laboratory Findings
6. Diagnosis
7. Treatment
8. Prognosis
9. Key Research Papers
10. Connections
11. Featured Videos

Overview

Wiskott-Aldrich Syndrome (WAS) is a rare X-linked primary immunodeficiency disorder characterized by profound immune dysregulation combined with thrombocytopenia (low platelet count with abnormally small platelets). It arises from loss-of-function mutations in the WAS gene located on chromosome Xp11.23, which encodes the Wiskott-Aldrich Syndrome protein (WASp). Because inheritance is X-linked, the disorder affects almost exclusively males, with an estimated prevalence of approximately 1 in 100,000 to 250,000 male births worldwide.

WASp is a cytoskeletal regulator expressed exclusively in hematopoietic cells. It acts as a molecular scaffold that links upstream signaling — particularly the small Rho GTPase CDC42 — to downstream actin polymerization via the Arp2/3 complex. When WASp is absent or non-functional, multiple immune-cell lineages fail to perform actin-dependent processes:

• T cells: Impaired immunological synapse formation, reduced activation and cytokine production.
• NK cells: Defective lytic granule polarization, reduced cytotoxicity against infected and tumor cells.
• B cells: Abnormal antigen-receptor signaling, poor class switching, especially to IgM → IgG for polysaccharide antigens.
• Regulatory T cells (Tregs): Reduced numbers and function, leading to paradoxical autoimmunity despite immunodeficiency.
• Platelets: Disordered megakaryocyte cytoskeletal dynamics producing characteristically small, fragile platelets (microplatelets) with accelerated peripheral destruction.
• Dendritic cells and macrophages: Impaired phagocytosis and antigen presentation.

The result is a combined B-cell and T-cell immunodeficiency superimposed on bleeding risk, with a significant propensity for autoimmune disease and malignancy in untreated or undertreated patients.

↑ Back to Table of Contents

The Classic Triad

The hallmark of classic Wiskott-Aldrich Syndrome is the simultaneous occurrence of three clinical features that together strongly suggest the diagnosis:

1. Thrombocytopenia with Microplatelets

The platelet abnormality in WAS is unique and diagnostically important. Unlike immune thrombocytopenic purpura (ITP), where the immune system destroys normal or large platelets, in WAS the platelets are intrinsically abnormal — they are small (low mean platelet volume, MPV) as well as reduced in number. Platelet counts typically range from 20,000 to 50,000/µL (normal 150,000–400,000/µL). The low MPV is a key distinguishing laboratory feature from ITP, where MPV is normal or elevated.

Bleeding manifestations include:

• Petechiae and purpura, often apparent in the first weeks of life.
• Bloody diarrhea in infants — a presenting sign that can be mistaken for cow's-milk allergy or inflammatory bowel disease.
• Prolonged bleeding from minor wounds.
• Intracranial hemorrhage (ICH) — the most feared acute complication and historically the leading cause of death in young WAS patients.

2. Eczema

Atopic dermatitis in WAS is often severe and begins in early infancy, frequently as the first or most prominent feature. The eczema can be indistinguishable from severe atopic dermatitis of other causes but is characteristically refractory to standard topical therapies and prone to superinfection, particularly with Staphylococcus aureus, Herpes simplex, and Eczema herpeticum. It is driven by dysregulated Th2 skewing and elevated IgE, reflecting the underlying immune imbalance.

3. Recurrent Infections

WAS produces a combined humoral and cellular immunodeficiency. The antibody deficiency is selective but clinically significant — patients have a characteristically poor response to T-independent type 2 antigens (polysaccharide capsule components), making them uniquely vulnerable to encapsulated organisms:

• Streptococcus pneumoniae (pneumonia, bacteremia, meningitis)
• Haemophilus influenzae type b (meningitis, epiglottitis)
• Neisseria meningitidis (meningococcemia)

Viral susceptibility is also elevated, particularly to herpesviruses:

• Cytomegalovirus (CMV) — disseminated disease
• Epstein-Barr virus (EBV) — reactivation, lymphoproliferation
• Herpes simplex virus (HSV) — eczema herpeticum
• Varicella-zoster virus (VZV) — severe or disseminated chickenpox

Opportunistic infections (Pneumocystis jirovecii pneumonia, fungal infections) occur particularly in patients with severe WASp deficiency.

↑ Back to Table of Contents

Disease Spectrum

WAS is not a single uniform phenotype. Depending on the nature of the WAS gene mutation and residual WASp function, the clinical picture spans a wide spectrum. A clinical severity score (WAS score 1–5) is widely used:

• Score 1–2 — X-Linked Thrombocytopenia (XLT): The mildest end of the spectrum. Patients have thrombocytopenia with small platelets but minimal or no eczema and only mild, recurrent (not severe) infections. WASp is partially functional. Many XLT patients are diagnosed incidentally or after a bleeding event in childhood. Near-normal lifespan is possible with supportive care.
• Score 3–4 — Classic WAS: The full triad of thrombocytopenia, eczema, and recurrent combined infections. WASp is absent or severely reduced. Without hematopoietic stem cell transplantation (HSCT), prognosis is poor.
• Score 5 — Severe WAS with autoimmunity or malignancy: WASp-null state with paradoxical autoimmune disease arising from regulatory T cell (Treg) dysfunction. These patients suffer from both immunodeficiency and immune-mediated tissue damage simultaneously.

Female Carriers

Female carriers of WAS mutations are typically asymptomatic due to preferential X-inactivation that silences the mutant allele in hematopoietic cells. However, in carriers with unfavorable (non-skewed) X-inactivation, mild thrombocytopenia may occur. Rarely, a female with Turner syndrome (45,X) or compound heterozygosity can be fully affected.

X-Linked Neutropenia (XLN)

A distinct gain-of-function mutation in the GBD domain of WAS (L270P and I294T alleles) causes X-linked neutropenia with myelodysplasia, without thrombocytopenia — the opposite end of the WASp dysfunction spectrum. This underscores the role of WASp in myeloid lineage regulation beyond just immune cells and platelets.

↑ Back to Table of Contents

Complications

Untreated or undertreated Wiskott-Aldrich Syndrome carries four major categories of life-threatening or debilitating complications:

Bleeding

Intracranial hemorrhage (ICH) is the most feared acute complication and was historically the most common cause of early death. Even minor head trauma can precipitate ICH in a child with a platelet count of 20,000–30,000/µL. Gastrointestinal bleeding, epistaxis, and bleeding after dental procedures or surgery are also significant risks throughout life.

Infections

Severe, recurrent bacterial infections — particularly meningitis and bacteremia from encapsulated organisms — were the second major cause of death in the pre-IVIG and pre-HSCT era. Opportunistic infections (PCP pneumonia, cryptococcal meningitis, disseminated CMV) occur in patients with significant T-cell dysfunction. EBV-driven lymphoproliferative disease bridges the infection and malignancy categories.

Malignancy

WAS patients face a 20- to 22-fold increased risk of malignancy compared with the general population. The vast majority are lymphomas, predominantly EBV-driven non-Hodgkin B-cell lymphomas (Burkitt-like, diffuse large B-cell). Leukemia and other hematologic malignancies also occur. Malignancy typically emerges in the second decade of life or later, and its risk is substantially eliminated by successful HSCT.

Autoimmunity (Paradoxical)

Approximately 40% of WAS patients develop significant autoimmune disease — a counterintuitive finding given the underlying immunodeficiency. The mechanism is Treg dysfunction: WASp-deficient regulatory T cells fail to adequately suppress autoreactive clones. Manifestations include:

• Autoimmune hemolytic anemia (AIHA) — most common autoimmune complication
• Vasculitis (including cerebral vasculitis)
• Immune nephritis
• Inflammatory bowel disease-like enteropathy
• Arthritis
• Autoimmune cytopenias

The coexistence of autoimmunity worsens prognosis and increases the urgency of definitive HSCT.

↑ Back to Table of Contents

Laboratory Findings

The laboratory profile of WAS is distinctive and, when the full pattern is recognized, strongly supports the diagnosis before molecular confirmation:

• Thrombocytopenia with low MPV (microplatelets): This combination — low platelet count AND low mean platelet volume — is the diagnostic hallmark. In ITP, platelets are large (high MPV) because the bone marrow compensates by releasing immature, large platelets. In WAS, the platelets are intrinsically small due to the cytoskeletal defect in megakaryocytes.
• Low IgM: Often markedly reduced; polysaccharide-specific IgM responses are disproportionately impaired.
• Low to normal IgA: Reduced in many patients.
• Normal or elevated IgG and IgE: IgG may be normal or low depending on disease severity; IgE is often elevated, reflecting Th2 skewing and eczema.
• Poor vaccine responses: Impaired antibody responses to T-independent polysaccharide vaccines (pneumococcal polysaccharide, unconjugated Hib) — a functional test distinguishing WAS from simple quantitative antibody deficiencies.
• Impaired NK cell cytotoxicity: Reducible by chromium-release assay; reflects WASp's critical role in lytic granule polarization.
• Reduced or absent WASp protein by intracellular flow cytometry: This is the first-line confirmatory test after clinical suspicion. Intracellular staining of peripheral blood mononuclear cells (PBMCs) using an anti-WASp antibody rapidly identifies absent or severely reduced WASp expression.
• WAS gene sequencing: Definitive molecular confirmation. Over 300 distinct mutations have been identified (missense, nonsense, splice-site, small insertions/deletions). Genotype-phenotype correlation exists but is imperfect.
• Lymphocyte subsets: T- and B-cell counts are often normal in early childhood but progressive T-cell lymphopenia develops over time, particularly CD8+ T cells. NK cells are present but functionally impaired.

↑ Back to Table of Contents

Diagnosis

The diagnosis of WAS should be considered in any male infant or child presenting with:

• Thrombocytopenia with small platelets (low MPV) — especially if present from birth or early infancy
• Bloody diarrhea in infancy (often misattributed to cow's-milk protein allergy)
• Severe or recurrent infections disproportionate to age
• Severe atopic eczema unresponsive to standard therapy
• Any combination of the above classic triad features

Stepwise Diagnostic Approach

1. CBC with differential and smear: Confirm thrombocytopenia; examine platelet size and morphology. Automated MPV is the fastest clue — a low MPV in a thrombocytopenic male is WAS until proven otherwise.
2. Immunoglobulin quantification: IgG, IgA, IgM, IgE levels.
3. Vaccine antibody titers: Test responses to both protein (tetanus, diphtheria) and polysaccharide (pneumococcal) antigens; selective polysaccharide unresponsiveness is highly characteristic.
4. WASp protein expression by intracellular flow cytometry: The pivotal screening test. Absent or markedly reduced WASp in PBMCs confirms significant WAS gene dysfunction. A small percentage of patients with missense mutations produce a non-functional but detectable WASp; flow cytometry may be normal or near-normal in these cases.
5. WAS gene sequencing: Definitive confirmation and guides family counseling and prenatal testing. Next-generation sequencing panels covering the full coding sequence and splice sites are available in most reference laboratories.

Differential Diagnosis

• Immune thrombocytopenic purpura (ITP): Platelets are large (high MPV), no eczema, no recurrent infections, normal immunoglobulins. The most common initial misdiagnosis of WAS.
• Hemophilia A/B: Normal platelet count, normal platelet size, factor deficiency on coagulation studies.
• Atopic dermatitis alone: No thrombocytopenia, normal immune studies.
• Other primary immunodeficiencies: SCID (profound lymphopenia, absent T cells), XLA (no B cells, no IgG), CVID (normal/elevated MPV, normal platelets, adult onset).
• Bernard-Soulier syndrome: Large platelets (high MPV), GPIb/IX/V deficiency — opposite MPV to WAS.

Prenatal and Carrier Diagnosis

When the family mutation is known, prenatal diagnosis by chorionic villus sampling (CVS) or amniocentesis is available. Carrier testing of at-risk female relatives by WAS gene sequencing allows family planning and preparation for an affected pregnancy.

↑ Back to Table of Contents

Treatment

Management of WAS is stratified by disease severity and the availability of a suitable hematopoietic stem cell transplant (HSCT) donor. For all patients, supportive measures begin immediately at diagnosis.

Supportive and Prophylactic Therapy

• IVIG (intravenous immunoglobulin): 400–600 mg/kg every 3–4 weeks. Reduces bacterial infection frequency by supplementing deficient IgG and specific antibodies. Does not correct the cellular immune defect.
• Antimicrobial prophylaxis: Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia (PCP) prevention is standard for all patients with significant WASp deficiency. Antifungal prophylaxis (fluconazole) is added for patients with severe T-cell dysfunction.
• Vaccination: Live attenuated vaccines (MMR, live varicella) are contraindicated in classic WAS due to risk of vaccine-strain dissemination. Inactivated vaccines are given but elicit suboptimal responses. Post-exposure prophylaxis with VZV immunoglobulin (VariZIG) is used after varicella exposure.
• Platelet transfusions: Reserved for active significant bleeding or pre-procedurally. Routine prophylactic transfusion is not recommended due to alloimmunization risk and the chronicity of the thrombocytopenia.
• Eczema management: Topical corticosteroids, emollients, calcineurin inhibitors; early treatment of superinfections. Systemic immunosuppression for severe eczema requires careful balancing against infection risk.

Hematopoietic Stem Cell Transplantation (HSCT) — Curative

HSCT is the only proven curative therapy for WAS. It replaces the patient's defective hematopoietic system with donor-derived cells that carry a functional WAS gene, correcting all three arms of the classic triad — thrombocytopenia, immune deficiency, and (over time) eczema.

• Best outcomes: HLA-matched sibling donor, age under 5 years, before complications (autoimmunity, organ damage, malignancy) develop. Survival rates exceed 90% in this group.
• Matched unrelated donor (MUD) HSCT: Acceptable outcomes when no sibling donor is available, particularly in young children. Outcomes with 10/10 HLA-matched unrelated donors have improved significantly with modern conditioning and graft-versus-host disease (GVHD) prophylaxis.
• Haploidentical and cord-blood transplants: Used when no matched donor is available; higher GVHD and graft failure risk, but outcomes improving with T-cell depletion strategies.
• Timing: The European Society for Immunodeficiencies (ESID) and Inborn Errors Working Party guidelines recommend transplantation as early as feasible after diagnosis in classic WAS, ideally before 5 years of age.

Gene Therapy

Lentiviral vector-based gene therapy has emerged as a curative alternative for patients lacking a matched donor. The autologous approach — transducing the patient's own hematopoietic stem cells with a functional WAS cDNA under control of the endogenous WAS promoter — avoids GVHD entirely. The OTL-103 (Strimvelis-like) program developed by the San Raffaele Institute (Milan) and its commercial successor have demonstrated:

• Durable WASp reconstitution in T cells, B cells, NK cells, and platelets beyond 5 years follow-up.
• Resolution of thrombocytopenia (platelet normalization) in the majority of treated patients.
• No insertional oncogenesis events to date with SIN (self-inactivating) lentiviral vectors (a concern with earlier gammaretroviral vectors in other PIDs).
• Regulatory approval granted in some jurisdictions; ongoing clinical trials expanding access.

Splenectomy

Splenectomy significantly raises platelet counts (by removing the primary site of platelet destruction) but substantially increases the risk of overwhelming post-splenectomy sepsis with encapsulated organisms. In a patient who already has impaired polysaccharide antibody responses, this risk is amplified. Splenectomy is generally avoided as definitive management and should not be performed before or instead of HSCT workup.

↑ Back to Table of Contents

Prognosis

The prognosis of WAS has been transformed by HSCT and, more recently, gene therapy. The natural history — without curative treatment — is poor:

• Historically, median survival was approximately 15 years, with death most commonly from ICH in early childhood, severe infections in childhood and adolescence, or EBV-driven lymphoma in the second or third decade.
• Autoimmune complications further worsen prognosis in WASp-null patients and may independently contribute to organ failure (renal, CNS vasculitis).

With modern treatment:

• Matched sibling HSCT before age 5: Overall survival exceeds 90%. The classic triad resolves — platelets normalize, immune competence is restored, eczema clears. Risk of lymphoma is eliminated in successfully engrafted patients. Quality of life approaches that of the general population.
• Matched unrelated donor HSCT: Outcomes approach sibling-matched HSCT in experienced centers with 10/10 HLA-matched donors and modern GVHD prophylaxis protocols.
• Gene therapy (OTL-103 and successor programs): Phase I/II data show durable correction beyond 5 years. Platelet reconstitution occurs in most patients. No lymphoma events post-gene therapy have been reported in WAS patients. Long-term survival data are still maturing.
• X-Linked Thrombocytopenia (XLT) — mild spectrum: Patients with partial WASp expression and the XLT phenotype can achieve near-normal lifespan with watchful waiting, IVIG, and avoidance of bleeding triggers. HSCT or gene therapy may still be appropriate in XLT patients with high bleeding burden or progressive disease.

Early diagnosis remains the most modifiable prognostic factor. Newborn screening programs using next-generation sequencing (NGS) panels — or TREC/KREC-based screening extended to WAS — have the potential to identify affected boys before their first serious complication, enabling early transplantation and optimal outcomes.

↑ Back to Table of Contents

Key Research Papers

The following peer-reviewed publications represent foundational and landmark research in the understanding and treatment of Wiskott-Aldrich Syndrome:

1. Derry JM, Ochs HD, Francke U. (1994). Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 78(4):635–644. PMID: 8069912
2. Symons M, Derry JM, Karlak B, et al. (1996). Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 84(5):723–734. PMID: 8625410
3. Snapper SB, Rosen FS. (1999). The Wiskott-Aldrich syndrome protein (WASp): roles in signaling and cytoskeletal organization. Annual Review of Immunology. 17:905–929. PMID: 10358777
4. Filipovich AH, Stone JV, Tomany SC, et al. (2001). Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 97(6):1598–1603. PMID: 11238097
5. Imai K, Morio T, Zhu Y, et al. (2004). Clinical course of patients with WASP gene mutations. Blood. 103(2):456–464. PMID: 14504097
6. Aiuti A, Biasco L, Scaramuzza S, et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 341(6148):1233151. PMID: 23845947
7. Moratto D, Giliani S, Bonfim C, et al. (2011). Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 118(6):1675–1684. PMID: 21659544
8. Massaad MJ, Ramesh N, Bhatt DL, Geha RS. (2013). Wiskott-Aldrich syndrome: a comprehensive review. Annals of the New York Academy of Sciences. 1285:26–43. PMID: 23527602
9. Humblet-Baron S, Sather B, Anover S, et al. (2007). Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. Journal of Clinical Investigation. 117(2):407–418. PMID: 17273558
10. Braun CJ, Witzel M, Paruzynski A, et al. (2014). Gene therapy for Wiskott-Aldrich Syndrome — long-term efficacy and genotoxicity. Science Translational Medicine. 6(227):227ra33. PMID: 24523320
11. Puck JM, Candotti F. (2006). Lessons from the Wiskott-Aldrich syndrome. New England Journal of Medicine. 355(17):1759–1761. PMID: 17065635
12. Ochs HD, Thrasher AJ. (2006). The Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology. 117(4):725–738. PMID: 16630929

↑ Back to Table of Contents

Connections

• Common Variable Immunodeficiency (CVID)
• Severe Combined Immunodeficiency (SCID)
• X-Linked Agammaglobulinemia (XLA)
• IgA Deficiency
• Chronic Granulomatous Disease
• Immunology — All Conditions
• Diseases — All Categories

↑ Back to Table of Contents

Featured Videos